Schedule an appointment with your healthcare provider
Safety data indicate retatrutide is typically well-tolerated
50+ Years of experience 150+ Ongoing CMC projects 2,500+ Team members globally Our peptide and oligonucleotide CDMO services End-to-end CDMO support for peptide and oligonucleotide therapeutics
Liver diseases, including cirrhosis and hepatitis, and kidney diseases like chronic kidney disease and nephrotic syndrome, may also be managed with this formulation
FAQs Are headaches a common side effect of GLP-1 injections
Other characteristic features of this lesion include small aggregates of damaged-appearing capillary-sized vessels, perivascular hyalinization, and scattered tumor cells with enlarged, pleomorphic nuclei and intranuclear pseudoinclusions